Cannabis extraction services provider The Valens Company (CVE:VLNS, OTCMKTS: VLNCF) reported earnings that exceeded expectations
Revenue came in at C$30.6 million, 11% better than consensus of C$28 million and guidance of C$27-C$30 million.
Revenue was up 85% over last quarter, down only slightly from 87% growth the quarter before and 300% in the company’s first quarter with public filings.
Results benefitted from an increase in the white label business which creates assorted products for other producers who slap their brand on the “White Label”.
White label expertise is how Valen’s is going to differentiate itself and avoid commoditization of the extraction business longer term.
EBITDA of C$17.7 million crushed the analyst estimate of C$12 million.
The market will likely be happy with these results and the company’s stock outperformance against peers should continue.
Valens has really started to separate from the other extractors with solid execution and a much smarter strategy given current industry dynamics.
Main competitor Medipharm Labs was impacted by a dispute with a customer earlier this year, which hammered the stock.
Performance of MediPharm and Valens (Last 6 Months)
Other producers are either struggling to ramp up quickly enough or are relying on the profitable but risky strategy of buying cannabis and selling extracts at the going market rate instead of through long term contracts.
Valens, in contrast, is signing long term contracts to extract the flower of others and also provide packaged products that other producers can buy and slap their own brand on.
Valens is saving producers time and the big upfront cash outlays required to extract flower in-house.
Financial distress in the Canadian cannabis space remains a risk for extraction company’s who generally rely on these same companies for all of their revenue.
An acute oversupply in the market will also filter down to extractors impacting their growth prospects and margins, which are far too high as a % of the revenue their customers make selling that same product.
Consensus P/S Multiples for Valens, Medipharm and Neptune
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.